Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usability of CT-P17 Auto-injector in Moderate to Severe Active Rheumatoid Arthritis
2019-000660-25Phase 3Completed
- Sponsor
- Celltrion
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of RT-105 in rheumatoid arthritis (RA), sponsored by Celltrion. Primary endpoint: Primary usability endpoint. Started May 2019; status: completed.
02
Drugs
RT-105
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-000660-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000660-25.